Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

Makiyama, Akitaka; Sukawa, Yasutaka; Kashiwada, Tomomi; Kawada, Junji; Hosokawa, Ayumu; Horie, Yoshiki; Tsuji, Akihito; Moriwaki, Toshikazu; Tanioka, Hiroaki; Shinozaki, Katsunori; Uchino, Keita; Yasui, Hirofumi; Tsukuda, Hiroshi; Nishikawa, Kazuhiro; Ishida, Hiroyasu; Yamanaka, Takeharu; Yamazaki, Kentaro; Hironaka, Shuichi; Esaki, Taito; Boku, Narikazu; Hyodo, Ichinosuke; Muro, Kei

doi:10.1200/jco.19.03077

Public

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

Published in Journal of Clinical Oncology • Mar 25, 2020

Authors:

Akitaka Makiyama

Yasutaka Sukawa

Tomomi Kashiwada

Abstract

PURPOSE This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. PATIENTS AND METHODS Patients with HER2-positive advanced G/GEJ cancer refractory to first...

Subject

Medicine

Trastuzumab

Gastroesophageal Junction

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!